Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10583101-B2

Patent

Publication Date

2020-03-10

Expiration Date


Abstract

The present invention relates to a pharmaceutical lipid composition comprising nitrosoureas and process for its preparation. In particular, the compositions of present invention are useful in the treatment of brain cancers having improved physicochemical and pharmacokinetic characteristics.

Core Innovation

The invention describes a stable, lyophilized carmustine–lipid suspension for injection. Carmustine is encapsulated or complexed in lipid, with a buffer in the composition; the disclosure also identifies formulations containing a preservative or antioxidant, a surfactant, and an osmogen. The claims define particle-size limits for the lipid-encapsulated or complexed carmustine and carmustine-to-lipid ratios.

The partial content does not include the background section, so the problem being solved is not explicitly described in patent. The described composition is suitable for dilution with aqueous vehicles and is identified as being for injection. The description reports stability criteria and evaluation results that include particle sizes of 48.8–57.3 nm and drug entrapment of 75.9–78.1%.

Claims Coverage

The two independent claims cover two inventive features: a stable lipid suspension composition containing lyophilized carmustine, and a lyophilized carmustine composition suitable for dilution with aqueous vehicles.

Stable lipid suspension composition

Claim 1 covers a stable lipid suspension composition comprising a lyophilized powder with carmustine, a buffer, and a lipid. The lipid encapsulates or complexes the carmustine, and the claim specifies a carmustine-to-lipid ratio of about 1:1 to about 1:25 and a particle size of less than 200 nm.

Lyophilized carmustine composition suitable for aqueous dilution

Claim 10 covers a lyophilized carmustine composition suitable for dilution with aqueous vehicles, comprising carmustine, a selected buffer, lipid, preservative or antioxidant, surfactant, and osmogen. The lipid encapsulates or complexes the carmustine, with a carmustine-to-lipid ratio of about 1:10 to about 1:25 and a particle size of less than 100 nm.

The claims cover a lyophilized carmustine composition in which lipid encapsulates or complexes carmustine, with specified component selections, ratios, and particle-size limits. One independent claim covers the stable lipid suspension; the other specifies a composition suitable for dilution with aqueous vehicles and includes additional component classes.

Stated Advantages

Not explicitly described in patent.

Documented Applications

The stable lyophilized carmustine–lipid suspension is described for injection.

The lyophilized carmustine composition of claim 10 is suitable for dilution with aqueous vehicles.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.